Abstract
Human glutaminyl cyclase (hQC) appeared as a promising new target with its inhibitors attracted much attention for the treatment of Alzheimer’s disease (AD) in recent years. But so far, only a few compounds have been reported as hQC inhibitors. To find novel and potent hQC inhibitors, a high-specificity ZBG (zinc-binding groups)-based pharmacophore model comprising customized ZBG feature was first generated using HipHop algorithm in Discovery Studio software for screening out hQC inhibitors from the SPECS database. After purification by docking studies and drug-like ADMET properties filters, four potential hit compounds were retrieved. Subsequently, these hit compounds were subjected to 30-ns molecular dynamic (MD) simulations to explore their binding modes at the active side of hQC. MD simulations demonstrated that these hit compounds formed a chelating interaction with the zinc ion, which was consistent with the finding that the electrostatic interaction was the major driving force for binding to hQC confirmed with MMPBSA energy decomposition. Higher binding affinities of these compounds were also verified by the binding free energy calculations comparing with the references. Thus, these identified compounds might be potential hQC candidates and could be used for further investigation.
Similar content being viewed by others
References
Kayalvili, S. (2015). Depression is a risk factor for Alzheimer disease-review. Research Journal of Pharmacy and Technology, 8(8), 1056–1058. https://doi.org/10.5958/0974-360X.2015.00181.X.
Anna, M., Andrea, M., Elena, S., Michela, R., Maria, B. L., Chiara, M., & Vincenzo, T. (2013). Multifunctional tacrine derivatives in Alzheimer’s disease. Current Topics in Medicinal Chemistry, 13(15), 1771–1786. https://doi.org/10.2174/15680266113139990136.
Yang, Y. H., Chen, C. H., Chou, M. C., Li, C. H., Liu, C. K., & Chen, S. H. (2013). Concentration of donepezil to the cognitive response in Alzheimer disease. Journal of Clinical Psychopharmacology, 33(3), 351–355. https://doi.org/10.1097/JCP.0b013e31828b5087.
Desai, A. K., & Grossberg, G. T. (2005). Rivastigmine for Alzheimer’s disease. Expert Review of Neurotherapeutics, 5(5), 563–580. https://doi.org/10.1586/14737175.5.5.563.
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & van Hoesen, G. W. (1991). The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex, 1(1), 103–116. https://doi.org/10.1093/cercor/1.1.103.
Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., & Pilotto, A. (2009). Beyond the neurotransmitter-focused approach in treating Alzheimer’s disease: drugs targeting β-amyloid and tau trotein. Aging Clinical and Experimental Research, 21(6), 386–406. https://doi.org/10.1007/BF03327445.
Awadé, A. C., Cleuziat, P., GonzalèS, T., & Robert-Baudouy, J. (1994). Pyrrolidone carboxyl peptidase (Pcp): an enzyme that removes pyroglutamic acid (pGlu) from pGlu-peptides and pGlu-proteins. Proteins, 20(1), 34–51. https://doi.org/10.1002/prot.340200106.
Abraham, G. N., & Podell, D. N. (1981). Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Molecular and Cellular Biochemistry, 38(1), 181–190. https://doi.org/10.1007/BF00235695.
van Coillie, E., Proost, P., van Aelst, I., Struyf, S., Polfliet, M., de Meester, I., Harvey, D. J., van Damme, J., & Opdenakker, G. (1998). Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry, 37(36), 12672–12680. https://doi.org/10.1021/bi980497d.
Busby, W. H., Quackenbush, G. E., Humm, J., Youngblood, W. W., & Kizer, J. S. (1987). An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. Journal of Biological Chemistry, 262(18), 8532–8536 http://www.jbc.org/content/262/18/8532.short.
Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C. M., Shoji, M., & Younkin, S. G. (2000). Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochemical and Biophysical Research Communications, 276(2), 422–427. https://doi.org/10.1006/bbrc.2000.3490.
Gunn, A. P., Masters, C. L., & Cherny, R. A. (2010). Pyroglutamate-Abeta: role in the natural history of Alzheimer’s disease. International Journal of Biochemistry & Cell Biology, 42(12), 1915–1918. https://doi.org/10.1016/j.biocel.2010.08.015.
Jawhar, S., Wirths, O., & Bayer, T. A. (2011). Pyroglutamate-Aβ: a hatchet man in Alzheimer disease. Journal of Biological Chemistry, 286(45), 38825–38832. https://doi.org/10.1074/jbc.R111.288308.
Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Böhm, G., & Demuth, H. U. (2006). On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry, 45(41), 12393–12399. https://doi.org/10.1021/bi0612667.
Schlenzig, D., Manhart, S., Cinar, Y., Kleinschmidt, M., Hause, G., Willbold, D., Funke, S. A., Schilling, S., & Demuth, H. U. (2009). Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry, 48(29), 7072–7078. https://doi.org/10.1021/bi900818a.
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., Reymann, K., Hutter-Paier, B., Alexandru, A., Jagla, W., Graubner, S., Glabe, C. G., Demuth, H. U., & Bloom, G. S. (2012). Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated β-amyloid. Nature, 485, 651–655. https://doi.org/10.1038/nature11060.
Alexandru, A., Jagla, W., Graubner, S., Becker, A., Bäuscher, C., Kohlmann, S., Sedlmeier, R., Raber, K. A., Cynis, H., Rönicke, R., Reymann, K. G., Petrasch-Parwez, E., Hartlage-Rübsamen, M., Waniek, A., Rossner, S., Schilling, S., Osmand, A. P., Demuth, H. U., & von Hörsten, S. (2011). Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. Journal of Neuroscience, 31(36), 12790–12801. https://doi.org/10.1523/JNEUROSCI.1794-11.2011.
Wu, G., Miller, R. A., Connolly, B., Marcus, J., Renger, J., & Savage, M. J. (2014). Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. Neurodegenerative Diseases, 14(2), 53–66. https://doi.org/10.1159/000353634.
Kuo, Y. M., Emmerling, M. R., Woods, A. S., Cotter, R. J., & Roher, A. E. (1997). Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochemical and Biophysical Research Communications, 237(1), 188–191. https://doi.org/10.1111/j.1471-4159.2008.05471.x.
Böckers, T. M., Kreutz, M. R., & Pohl, T. (1995). Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. Journal of Neuroendocrinology, 7(6), 445–453. https://doi.org/10.1111/j.1365-2826.1995.tb00780.x.
Schilling, S., Niestroj, A. J., Rahfeld, J. U., Hoffmann, T., Wermann, M., Zunkel, K., Wasternack, C., & Demuth, H. U. (2003). Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. Journal of Biological Chemistry, 278(50), 49773–49779. https://doi.org/10.1074/jbc.M309077200.
Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castaño, E. M., & Frangione, B. (1998). β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Medicine, 4, 822–826. https://doi.org/10.1038/nm0798-822.
Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994). The diagnosis of osteoporosis. Journal of Bone and Mineral Research, 9(8), 1137–1141. https://doi.org/10.1002/jbmr.5650090802.
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham III, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., Combe, B., Costenbader, K. H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Hobbs, K., Huizinga, T. W. J., Kavanaugh, A., Kay, J., Kvien, T. K., Laing, T., Mease, P., Ménard, H. A., Moreland, L. W., Naden, R. L., Pincus, T., Smolen, J. S., Stanislawska-Biernat, E., Symmons, D., Tak, P. P., Upchurch, K. S., Vencovský, J., Wolfe, F., & Hawker, G. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis and Rheumatism, 62(9), 2569–2581. https://doi.org/10.1002/art.27584.
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711–723. https://doi.org/10.1056/NEJMoa1003466.
Jawhar, S., Wirths, O., Schilling, S., Graubner, S., Demuth, H. U., & Bayer, T. A. (2011). Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. Journal of Biological Chemistry, 286(6), 4454–4460. https://doi.org/10.1074/jbc.M110.185819.
Morawski, M., Hartlage-Rübsamen, M., Jäger, C., Waniek, A., Schilling, S., Schwab, C., McGeer, P. L., Arendt, T., Demuth, H., & Roßner, S. (2010). Distinct glutaminyl cyclase expression in edinger-westphal nucleus, locus coeruleus and nucleus basalis meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease. Acta Neuropathologica, 120(2), 195–207. https://doi.org/10.1007/s00401-010-0685-y.
Hartlage-Rübsamen, M., Morawski, M., Waniek, A., Jäger, C., Zeitschel, U., Koch, B., Cynis, H., Schilling, S., Schliebs, R., Demuth, H., & Roßner, S. (2011). Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathologica, 121(6), 705–719. https://doi.org/10.1007/s00401-011-0806-2.
Schilling, S., Appl, T., Hoffmann, T., Cynis, H., Schulz, K., Jagla, W., Friedrich, D., Wermann, M., Buchholz, M., Heiser, U., von Hrsten, S., & Demuth, H. U. (2008). Inhibition of glutaminyl cyclase prevents pGlu-Aβ formation after intracortical/hippocampal micro-injection in vivo/in situ. Journal of Neurochemistry, 106(3), 1225–1236. https://doi.org/10.1111/j.1471-4159.2008.05471.x.
Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., Jagla, W., Schlenzig, D., Lindner, C., Rudolph, T., Reuter, G., Cynis, H., Montag, D., Demuth, H. U., & Rossner, S. (2008). Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathology. Nature Medicine, 14, 1106–1111. https://doi.org/10.1038/nm.1872.
Schilling, S., Hoffmann, T., Wermann, M., Heiser, U., Wasternack, C., & Demuth, H. U. (2002). Continuous spectrometric assays for glutaminyl cyclase activity. Analytical Biochemistry, 303(1), 49–56. https://doi.org/10.1006/abio.2001.5560.
Schilling, S., Hoffmann, T., Rosche, F., & Manhart, S. (2002). Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity. Biochemistry, 41(35), 10849–10857. https://doi.org/10.1021/bi0260381.
Ruiz Carrillo, D., Koch, B., Parthier, C., Wermann, M., Dambe, T., Buchholz, M., Ludwig, H. H., Heiser, U., Rahfeld, J. U., Stubbs, M. T., Schilling, S., & Demuth, H. U. (2011). Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center. Biochemistry, 50(28), 6280–6288. https://doi.org/10.1021/bi200249h.
Buchholz, M., Heiser, U., Schilling, S., Niestroj, A. J., Zunkel, K., & Demuth, H. U. (2006). The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. Journal of Medicinal Chemistry, 49(2), 664–677. https://doi.org/10.1021/jm050756e.
Buchholz, M., Hamann, A., Aust, S., Brandt, W., Böhme, L., Hoffmann, T., Schilling, S., Demuth, H. U., & Heiser, U. (2009). Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. Journal of Medicinal Chemistry, 52(22), 7069–7080. https://doi.org/10.1021/jm900969p.
Huang, K. F., Liaw, S. S., Huang, W. L., Chia, C. Y., Lo, Y. C., Chen, Y. L., & Wang, A. H. J. (2011). Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. Journal of Biological Chemistry, 286(14), 12439–12449. https://doi.org/10.1074/jbc.M110.208595.
Koch, B., Kolenko, P., Buchholz, M., Ruiz Carrillo, D., Parthier, C., Wermann, M., Rahfeld, J. U., Reuter, G., Schilling, S., Stubbs, M. T., & Demuth, H. U. (2012). Crystal structures of glutaminyl cyclases (QCs) from drosophila melanogaster reveal active site conservation between insect and mammalian QCs. Biochemistry, 51(37), 7383–7392. https://doi.org/10.1021/bi300687g.
Koch, B., Buchholz, M., Wermann, M., Heiser, U., Schilling, S., & Demuth, H. U. (2012). Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed muta-genesis approach: implications for drug development. Chemical Biology & Drug Design, 80(6), 937–946. https://doi.org/10.1111/cbdd.12046.
Ramsbeck, D., Buchholz, M., Koch, B., Böhme, L., Hoffmann, T., Demuth, H. U., & Heiser, U. (2013). Structure–activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold. Journal of Medicinal Chemistry, 56(17), 6613–6625. https://doi.org/10.1021/jm4001709.
Tran, P. T., Hoang, V. H., Thorat, S. A., Kim, S. E., Ann, J., Chang, Y. J., Nam, D. W., Song, H., Mook-Jung, I., Lee, J., & Lee, J. (2013). Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl) propyl thiourea template. Bioorganic & Medicinal Chemistry, 21(13), 3821–3830. https://doi.org/10.1016/j.bmc.2013.04.005.
Heiser, U., Ramsbeck, D., Buchholz, M., & Niestroj, A. J. (2015). U.S. Patent No. 9,126,987. Washington, DC: U.S. Patent and Trademark Office.
Li, M., Dong, Y., Yu, X., Zou, Y., Zheng, Y., Bu, X., Quan, J., He, Z., & Wu, H. (2016). Inhibitory effect of flavonoids on human glutaminyl cyclase. Bioorganic & Medicinal Chemistry, 24(10), 2280–2286. https://doi.org/10.1016/10.1016/j.bmc.2016.03.064.
Hoang, V. H., Tran, P. T., Cui, M., Ngo, V. T., Ann, J., Park, J., Lee, J., Choi, K., Cho, H., & Kim, H. (2017). Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer's agents based on rational design. Journal of Medicinal Chemistry, 60(6), 2573–2590. https://doi.org/10.1021/acs.jmedchem.7b00098.
Yang, S. Y. (2010). Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discovery Today, 15(11), 444–450. https://doi.org/10.1016/j.drudis.2010.03.013.
van de Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: towards prediction paradise. Nature Reviews Drug Discovery, 2, 192–204. https://doi.org/10.1038/nrd1032.
Irwin, J. J., & Shoichet, B. K. (2005). ZINC-a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 177–182. https://doi.org/10.1021/ci049714+.
Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. Journal of Medicinal Chemistry, 55(14), 6582–6594. https://doi.org/10.1021/jm300687e.
Kirchmair, J., Markt, P., Distinto, S., Wolber, G., & Langer, T. (2008). Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—what can we learn from earlier mistakes. Journal of Computer-Aided Molecular Design, 22(3), 213–228. https://doi.org/10.1007/s10822-007-9163-6.
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1), 3–25. https://doi.org/10.1016/S0169-409X(96)00423-1.
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256.
Santos-Martins, D., Forli, S., Ramos, M. J., & Olson, A. J. (2014). AutoDock4Zn: an improved autodock force field for small-molecule docking to zinc metalloproteins. Journal of Chemical Information and Modeling, 54(8), 2371–2379. https://doi.org/10.1021/ci500209e.
Berendsen, H. J. C., van der Spoel, D., & van Drunen, R. (1995). GROMACS: a message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91(1), 43–56. https://doi.org/10.1016/0010-4655(95)00042-E.
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF chimera—a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084.
Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepei, J. L., Dror, R. O., & Shaw, D. E. (2010). Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins, 78, 1950–1958. https://doi.org/10.1002/prot.22711.
Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006). Automatic atom type and bond type perception in molecular mechanical calculations. Journal of Molecular Graphics & Modelling, 25(2), 247–260. https://doi.org/10.1016/j.jmgm.2005.12.005.
Sousa da Silva, A. W., & Vranken, W. F. (2012). ACPYPE-AnteChamber PYthon Parser interfacE. BMC Research Notes, 5, 367. https://doi.org/10.1186/1756-0500-5-367.
Cerutti, D. S., Duke, R. E., Darden, T. A., & Lybrand, T. P. (2009). Staggered mesh ewald: an extension of the smooth particle-mesh ewald method adding great versatility. Journal of Chemical Theory and Computation, 5(9), 2322–2338. https://doi.org/10.1021/ct9001015.
Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, G. E. M. (1997). LINCS: a linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO,2-H.
Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m.
Funding
This research received supports from the Science and Technology planning Project of Guangzhou (No. 2013J4100071) and the computation environment support by College of Pharmacy, SunYat-Sen University for Discovery Studio 2.5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Lin, W., Zheng, X., Fang, D. et al. Identifying hQC Inhibitors of Alzheimer’s Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis. Appl Biochem Biotechnol 187, 1173–1192 (2019). https://doi.org/10.1007/s12010-018-2780-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-018-2780-9